China's drug regulator approved CanSinoBIO's adsorbed tetanus vaccine for non-neonatal tetanus prevention, sending shares up 37.4 percent. The company also signed an exclusive commercialization agreement with Grand Life Sciences for the product.
Quay lại
CanSinoBIO shares jump 37% on NMPA tetanus vaccine approval
CanSinoBIO shares jumped 37.4 percent after China's National Medical Products Administration approved its adsorbed tetanus vaccine for non-neonatal tetanus prevention.
The approval adds a new commercialized product to CanSinoBIO's portfolio, the company said in an exchange filing. The vaccine is primarily intended for the prevention of non-neonatal tetanus, a potentially fatal disease caused by Clostridium tetani bacteria entering the body through contaminated wounds.
The company also entered into an exclusive commercialization agreement with Grand Life Sciences for the tetanus vaccine, covering distribution and market access across China. Short selling volume reached HK$89.52 million, representing 6.424 percent of total turnover on the day.
The approval strengthens CanSinoBIO's position in China's vaccine market as the country pushes for life-course immunization under its 15th Five-Year Plan for Disease Prevention and Control, issued in July by seven departments including the National Disease Control and Prevention Administration and the National Development and Reform Commission. The company's three-component DTaP vaccine Tripecia was approved in April, and its five-component Td5cp adolescent and adult booster received NDA acceptance on Aug. 16 after being granted Priority Review status in May.
China reported more than 470,000 pertussis cases in 2024, roughly 12 times the prior year, drawing sustained attention to disease prevention and control. CanSinoBIO's Td5cp candidate includes two additional pertussis antigens — FIM2 and FIM3 — beyond the three-component formulation, with each antigen individually purified and formulated at precise ratios for batch consistency.
The stock surge also coincided with positive market sentiment around Moderna's Phase III mRNA cancer vaccine trial results, which lifted sentiment across vaccine developers. CanSinoBIO's short interest ratio of 6.424 percent suggests elevated bearish positioning that may have contributed to the upside move.
The approval also positions CanSinoBIO to capture demand for tetanus booster vaccines in China's adult immunization market, which has historically been underserved. As the country's disease control strategy shifts toward life-course vaccination, the company's expanding portfolio of commercialized products could provide a more stable revenue base. CanSinoBIO trades on both the Hong Kong Stock Exchange (06185.HK) and Shanghai's STAR Market (688185.SH). Financial terms of the Grand Life Sciences agreement were not disclosed.
The approval gives CanSinoBIO its second commercialized vaccine this year and expands its addressable market beyond infant immunization. The exclusive partnership with Grand Life Sciences is expected to accelerate market penetration for the tetanus vaccine, while the Td5cp booster's regulatory outcome remains the next milestone for the company's adolescent and adult vaccine franchise.
This article is for informational purposes only and does not constitute investment advice.
